Piramal Pharma Solutions Achieves Notable Success in Customer Audits and Regulatory Approvals

Piramal Pharma Solutions: A Commitment to Quality and Compliance

In a notable achievement that underscores its commitment to excellence, Piramal Pharma Solutions (PPS) has completed more than 200 customer audits while securing over 70 approvals from various regulatory agencies globally over the past fiscal year. This remarkable track record highlights the effectiveness and robustness of its long-term quality strategy, centered on sustained compliance and operational efficiency.

Strong Quality Governance Framework

Piramal Pharma Solutions has adopted a comprehensive quality governance framework that integrates multiple elements to ensure that all processes align with the highest quality standards. This framework includes proactive measures to remain audit-ready at all times, thereby addressing not only current regulatory requirements but also evolving expectations within the pharmaceutical industry.

At the helm of these efforts is Rashida Najmi, Chief Quality Officer, who emphasizes the philosophy that quality should be built into everyday operations to foster a culture of continuous improvement. The successful execution of this vision has helped the company maintain a high level of readiness across its diverse global operations.

Digital Transformation Enhancing Quality Processes

A significant aspect of PPS's strategy is its commitment to digital transformation. By leveraging innovative technologies, the company has been able to streamline and automate critical processes. For instance, the eLab platform digitizes quality control laboratories, significantly reducing manual errors and enhancing efficiency. Additionally, exForms helps digitize Good Manufacturing Practice (GxP) forms, which further supports compliance and expedites approval processes.

Moreover, the introduction of iAssist, a validated AI-enabled tool, aids in structuring investigations and enhancing consistency in outputs while reducing manual efforts for the teams. These digital advancements not only improve accuracy but also reinforce the ongoing commitment to maintaining a culture of quality.

A Proactive Approach to Regulatory Preparedness

Key initiatives within PPS's overall strategy include the RESOLVE program, aimed at ensuring first-time right execution in both manufacturing and quality control laboratories. This program focuses on minimizing errors through concurrent batch record reviews and enhancing overall operational vigilance. Specialized training programs aimed at improving audit readiness have also been implemented, fortifying the quality capabilities of the workforce.

With these measures in place, PPS has adeptly managed to navigate stringent regulations and expectations, continuously demonstrating its ability to deliver safe and effective therapies to patients around the world.

Commitment to Continuous Improvement

The outcomes of these extensive efforts are reflected in the increasing number of successful audits and regulatory approvals. This success is not just a benchmark but a testament to Piramal’s long-term dedication to achieving the highest standards of quality in every aspect of its operations.

As a leading Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions operates through a well-integrated global network, providing a wide range of services throughout the drug lifecycle. This comprehensive service portfolio has positioned PPS as a reliable partner for companies seeking quality-driven solutions for their pharmaceutical products.

Conclusion

The journey of Piramal Pharma Solutions demonstrates that the integration of robust quality governance, digital transformation, and a proactive approach towards regulatory compliance can lead to substantial accomplishments in the field of pharmaceuticals. This ensures a future where patient safety and access to effective therapies remain steadfast priorities within the global healthcare landscape. With this prevailing commitment to quality, PPS is well on its way to further cementing its status as a trusted leader in the pharmaceutical manufacturing industry.